brigatinib-resistant ALK mutants [plasma membrane]

Stable Identifier
Set [DefinedSet]
Homo sapiens
Locations in the PathwayBrowser
Literature References
PubMed ID Title Journal Year
25228534 Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

Okuno, Y, Iafrate, AJ, Friboulet, L, Koike, S, Shaw, AT, Engelman, JA, Khan, TM, Lockerman, EL, Takeuchi, K, Taiji, M, Fujita, N, Gainor, JF, Katayama, R

Clin Cancer Res 2014
27432227 Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Mino-Kenudson, M, Friboulet, L, Benes, CH, Engelman, JA, Yoda, S, DiCecca, RH, Digumarthy, S, Le, LP, Ritterhouse, LL, Lennerz, J, Sequist, LV, Muniappan, A, Parks, M, Gainor, JF, Schultz, K, Dardaei, L, Huynh, T, Iafrate, AJ, Keyes, C, Dias-Santagata, D, Heist, RS, Shaw, AT, Singh, M, Logan, J, Dagogo-Jack, I, Leshchiner, I, Channick, C, Lee, D, Chin, E, Lockerman, E, Getz, G, Gadgeel, S, Katayama, R

Cancer Discov 2016
23239810 Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors

Ceccon, M, Mologni, L, Scapozza, L, Bisson, W, Gambacorti-Passerini, C

Mol. Cancer Res. 2013
31668326 A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib

Cordani, N, Agustoni, F, Cortinovis, D, Arosio, G, Mologni, L, Sharma, GG, Pagni, F, Bidoli, P, Bisson, WH, Villa, M, Gambacorti-Passerini, C, Piazza, R

J Thorac Oncol 2019
25421750 Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma

Piazza, R, Ceccon, M, Giudici, G, Mologni, L, Fontana, D, Gambacorti-Passerini, C, Pirola, A

Mol. Cancer Res. 2015
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!